These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7614042)

  • 21. Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics.
    Masuko S; Linhardt RJ
    Future Med Chem; 2012 Mar; 4(3):289-96. PubMed ID: 22393937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the molecular mass dependency of heparin stimulation of heparin cofactor II:thrombin interaction to antithrombin III:thrombin interaction.
    Scully MF; Ellis V; Kakkar VV
    Thromb Res; 1987 May; 46(3):491-502. PubMed ID: 3603437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticoagulant properties of a fucoïdan fraction.
    Colliec S; Fischer AM; Tapon-Bretaudiere J; Boisson C; Durand P; Jozefonvicz J
    Thromb Res; 1991 Oct; 64(2):143-54. PubMed ID: 1811335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The anticoagulant properties of mast cell product, chondroitin sulphate E.
    Scully MF; Ellis V; Seno N; Kakkar VV
    Biochem Biophys Res Commun; 1986 May; 137(1):15-22. PubMed ID: 3087353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation.
    Bloemen S; Hemker HC; Al Dieri R
    Haematologica; 2013 Apr; 98(4):549-54. PubMed ID: 23100275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heparin-catalyzed inhibitor/protease reactions: kinetic evidence for a common mechanism of action of heparin.
    Griffith MJ
    Proc Natl Acad Sci U S A; 1983 Sep; 80(18):5460-4. PubMed ID: 6577437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
    Olson ST; Swanson R; Raub-Segall E; Bedsted T; Sadri M; Petitou M; Hérault JP; Herbert JM; Björk I
    Thromb Haemost; 2004 Nov; 92(5):929-39. PubMed ID: 15543318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limitations of conventional anticoagulant therapy and the promises of non-heparin based conformational activators of antithrombin.
    Rashid Q; Singh P; Abid M; Jairajpuri MA
    J Thromb Thrombolysis; 2012 Aug; 34(2):251-9. PubMed ID: 22453684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticoagulant activity of a sulfated galactan: serpin-independent effect and specific interaction with factor Xa.
    Glauser BF; Rezende RM; Melo FR; Pereira MS; Francischetti IM; Monteiro RQ; Rezaie AR; Mourão PA
    Thromb Haemost; 2009 Dec; 102(6):1183-93. PubMed ID: 19967150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticoagulant activity of artificial biomedical materials with co-immobilized antithrombin III and heparin.
    Miura Y; Aoyagi S; Ikeda F; Miyamoto K
    Biochimie; 1980; 62(8-9):595-601. PubMed ID: 7417594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Skeletal muscle myosin and cardiac myosin attenuate heparin's antithrombin-dependent anticoagulant activity.
    Morla S; Deguchi H; Griffin JH
    J Thromb Haemost; 2021 Feb; 19(2):470-477. PubMed ID: 33176060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ratios of anti-factor Xa to antithrombin activities of heparins as determined in recalcified human plasma.
    Schoen P; Lindhout T; Hemker HC
    Br J Haematol; 1992 Jun; 81(2):255-62. PubMed ID: 1322691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of inhibition of the prothrombinase complex by a covalent antithrombin-heparin complex.
    Stevic I; Berry LR; Chan AK
    J Biochem; 2012 Aug; 152(2):139-48. PubMed ID: 22518847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histones Differentially Modulate the Anticoagulant and Profibrinolytic Activities of Heparin, Heparin Derivatives, and Dabigatran.
    Ammollo CT; Semeraro N; Carratù MR; Colucci M; Semeraro F
    J Pharmacol Exp Ther; 2016 Feb; 356(2):305-13. PubMed ID: 26578266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate.
    Ofosu FA; Blajchman MA; Modi GJ; Smith LM; Buchanan MR; Hirsh J
    Br J Haematol; 1985 Aug; 60(4):695-704. PubMed ID: 2411283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma.
    Ofosu FA; Modi G; Cerskus AL; Hirsh J; Blajchman MA
    Thromb Res; 1982 Nov; 28(4):487-97. PubMed ID: 7164033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif--the C-domain.
    Al Dieri R; Wagenvoord R; van Dedem GW; Béguin S; Hemker HC
    J Thromb Haemost; 2003 May; 1(5):907-14. PubMed ID: 12871355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different glycoforms of human thrombomodulin. Their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III.
    Koyama T; Parkinson JF; Sié P; Bang NU; Müller-Berghaus G; Preissner KT
    Eur J Biochem; 1991 Jun; 198(3):563-70. PubMed ID: 1646716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.